Literature DB >> 27392913

Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.

Serra Arf1, Mumin Hocaoglu1, Isil Sayman Muslubas1, Murat Karacorlu2.   

Abstract

The purpose of the study was to evaluate the effect of reduced-fluence photodynamic therapy (RFPDT) for chronic central serous chorioretinopathy (CSC) associated with serous retinal detachment (SRD) and fovea-involving pigment epithelial detachment (PED). Ten eyes of ten patients with chronic CSC associated with combined SRD and PED involving the fovea were included. RFPDT was applied to the hyperfluorescent area identified at the mid-to-late phase of indocyanine green angiography, which indicated the area of leakage. We evaluated the changes in best-corrected visual acuity (BCVA) and optical coherence tomography at month 1 and final follow-up visit. The mean age of the participants was 47.4 ± 7 years. The mean follow-up duration was 6.3 ± 4 months. At month 3, the SRD had resolved completely in all ten eyes (100 %), and PED had resolved in seven eyes (70 %). The initial mean BCVA improved from 20/50 at baseline to 20/32 at the last visit (P > 0.05). The mean central retinal thickness was reduced from 534 ± 279 µm at baseline to 194 ± 46 µm at the last examination (P < 0.001). The mean subfoveal choroidal thickness decreased from 461 ± 57 at baseline to 369 ± 75 at the final visit (P < 0.001). Reduced-fluence PDT appears as an effective treatment for chronic CSC cases associated with SRD and fovea-involving PED.

Entities:  

Keywords:  Central serous chorioretinopathy; Fovea-involving pigment epithelial detachment; Indocyanine green angiography; Optical coherence tomography; Reduced-fluence photodynamic therapy; Serous retinal detachment

Mesh:

Substances:

Year:  2016        PMID: 27392913     DOI: 10.1007/s10792-016-0286-4

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  21 in total

1.  Photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  José M Ruiz-Moreno; Francisco L Lugo; Felix Armadá; Rufino Silva; Javier A Montero; J Fernando Arevalo; Luis Arias; Francisco Gómez-Ulla
Journal:  Acta Ophthalmol       Date:  2009-11-27       Impact factor: 3.761

2.  Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Joo Young Shin; Se Joon Woo; Hyeong Gon Yu; Kyu Hyung Park
Journal:  Retina       Date:  2011-01       Impact factor: 4.256

Review 3.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

4.  Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.

Authors:  T Y Y Lai; W-M Chan; H Li; R Y K Lai; D T L Liu; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-04-05       Impact factor: 4.638

5.  Long-term macular function in eyes with central serous chorioretinopathy.

Authors:  Nergis V Baran; Vuslat P Gürlü; Haluk Esgin
Journal:  Clin Exp Ophthalmol       Date:  2005-08       Impact factor: 4.207

6.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

7.  Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Ricky Y K Lai; David T L Liu; Dennis S C Lam
Journal:  Ophthalmology       Date:  2008-06-05       Impact factor: 12.079

Review 8.  Photodynamic therapy for central serous chorioretinopathy.

Authors:  O C Erikitola; R Crosby-Nwaobi; A J Lotery; S Sivaprasad
Journal:  Eye (Lond)       Date:  2014-06-20       Impact factor: 3.775

9.  The natural history of pigment epithelial detachment associated with central serous chorioretinopathy.

Authors:  Sachin S Mudvari; Mitchell J Goff; Arthur D Fu; H Richard McDonald; Robert N Johnson; Everett Ai; J Michael Jumper
Journal:  Retina       Date:  2007 Nov-Dec       Impact factor: 4.256

10.  Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Ricky Y K Lai; Emily W H Tang; David T L Liu; Dennis S C Lam
Journal:  Retina       Date:  2008-01       Impact factor: 4.256

View more
  4 in total

1.  Regression patterns of central serous chorioretinopathy using en face optical coherence tomography.

Authors:  Supriya Arora; Brian Rosario; Abdul Rasheed Mohammed; Oliver Beale; Amrish Selvam; Ramesh Venkatesh; Dmitrii S Maltsev; Jay Chhablani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-31       Impact factor: 3.535

2.  Improved thickness measurement method for choroidal hyperpermeability in central serous chorioretinopathy.

Authors:  Xing-Wang Chen; Fang-Yuan Han; Gang Su; Le Pan; Shan-Jun Cai
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

Review 3.  A Review of Central Serous Chorioretinopathy: Clinical Presentation and Management.

Authors:  Jerin Varghese; Dipanshu Kesharwani; Shreya Parashar; Prerna Agrawal
Journal:  Cureus       Date:  2022-08-13

4.  Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy.

Authors:  Thomas J van Rijssen; Danial Mohabati; Greet Dijkman; Thomas Theelen; Eiko K de Jong; Elon H C van Dijk; Camiel J F Boon
Journal:  PLoS One       Date:  2018-08-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.